Zacks: iRadimed Corporation (IRMD) Receives Consensus Rating of “Strong Buy” from Brokerages

Shares of iRadimed Corporation (NASDAQ:IRMD) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation. iRadimed Corporation’s rating score has improved by 50% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a 12 month consensus price objective of $16.00 for the company and are predicting that the company will post $0.06 earnings per share for the current quarter, according to Zacks. Zacks has also given iRadimed Corporation an industry rank of 168 out of 265 based on the ratings given to related companies.

IRMD has been the topic of a number of research analyst reports. Roth Capital upgraded iRadimed Corporation from a “neutral” rating to a “buy” rating and lifted their target price for the company from $9.00 to $12.00 in a report on Monday, July 31st. Zacks Investment Research upgraded iRadimed Corporation from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Friday, August 4th. Finally, ValuEngine upgraded iRadimed Corporation from a “sell” rating to a “hold” rating in a research note on Friday, October 6th.

iRadimed Corporation (NASDAQ IRMD) traded down $0.20 during trading on Monday, reaching $13.15. The company’s stock had a trading volume of 20,200 shares, compared to its average volume of 41,004. The stock has a market capitalization of $138.80, a P/E ratio of 101.15 and a beta of 1.67. iRadimed Corporation has a one year low of $7.85 and a one year high of $15.00.

iRadimed Corporation (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.35. The business had revenue of $5.69 million during the quarter, compared to the consensus estimate of $5.60 million. iRadimed Corporation had a return on equity of 4.58% and a net margin of 6.51%. The business’s revenue for the quarter was down 25.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.14 earnings per share. equities research analysts forecast that iRadimed Corporation will post 0.05 EPS for the current year.

WARNING: “Zacks: iRadimed Corporation (IRMD) Receives Consensus Rating of “Strong Buy” from Brokerages” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/11/20/zacks-iradimed-corporation-irmd-receives-consensus-rating-of-strong-buy-from-brokerages.html.

Several large investors have recently bought and sold shares of IRMD. AQR Capital Management LLC grew its holdings in shares of iRadimed Corporation by 25.9% during the first quarter. AQR Capital Management LLC now owns 137,663 shares of the medical equipment provider’s stock valued at $1,225,000 after purchasing an additional 28,345 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in iRadimed Corporation in the first quarter worth approximately $290,000. Federated Investors Inc. PA lifted its position in iRadimed Corporation by 7.5% in the second quarter. Federated Investors Inc. PA now owns 40,400 shares of the medical equipment provider’s stock worth $347,000 after purchasing an additional 2,807 shares during the period. Neuberger Berman Group LLC lifted its position in iRadimed Corporation by 23.3% in the second quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 3,500 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in shares of iRadimed Corporation during the 2nd quarter valued at $2,954,000. 14.68% of the stock is owned by institutional investors.

About iRadimed Corporation

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get a free copy of the Zacks research report on iRadimed Corporation (IRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply